Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS other · 2016-01-22

Clinical Trial Update: Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant afatinib for early-stage non-small cell lung cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Afatinib (afatinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: SUSPENDED